Titan Medical’s Head of Intellectual Property Recognized as a Global IP Strategy Leader by Intellectual Asset Management
June 20 2018 - 7:15AM
Titan Medical Inc. (“Titan” or the “Company”)
(TSX:TMD) (OTCQB:TITXD), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in minimally invasive surgery, announces
that Jasminder Brar, Titan Medical’s Director of Strategic
Development and Intellectual Property, was recognized by
Intellectual Asset Management (IAM) as a global IP strategy leader.
IAM, a leading IP business media platform, named
Mr. Brar to the 2018 edition of IAM Strategy 300 – The World’s
Leading IP Strategists. The guide lists the individuals that
in-depth research undertaken by a team in London, Washington, DC
and Hong Kong has shown possess world-class skills in the
development and roll-out of strategies that maximize the value of
patents, copyright, trademarks and other IP rights. Included in the
guide are third-party IP advisers as well as individuals working
inside operating companies, reflecting the growing importance that
businesses across the world attach to having in-house IP value
creation expertise.
This is the fourth consecutive year that Mr.
Brar has been included in the guide.
“Intellectual property continues to be
absolutely vital to our success and we are proud that Jasminder’s
leadership of our efforts and accomplishments has been recognized,”
said David McNally, President and CEO of Titan Medical. “I want to
congratulate Jasminder on his inclusion in the IAM Strategy 300 for
the fourth consecutive year and acknowledge his leadership and
know-how in advancing our strategic intellectual property
efforts.”
The 2018 edition of the guide can be found here
and a press release by IAM can be found here.
About Titan Medical Inc.
Titan Medical Inc. is focused on research and
development through to the planned commercialization of
computer-assisted robotic surgical technologies for application in
minimally invasive surgery. The Company is developing the SPORT
Surgical System, a single-port robotic surgical system. The SPORT
Surgical System is comprised of a surgeon-controlled patient cart
that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue focused surgical
indications for the SPORT Surgical System, which may include one or
more of gynecologic, urologic, colorectal or general abdominal
procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From May 2023 to May 2024